I can certainly agree the company has no control of the Journal, but I do believe that they should know its current status and any issues that remain to be resolved. They should have some idea of how long it will take.
As for the Annual Meeting having little or no import, I believe it all depends on how much information they release before the meeting. If we get the Journal, the TLD statement, and the company breaks the quiet period prior to the meeting and gives us the status of their approaching the regulators, the FlaskWorks unit certification, etc. then there may be little meaningful discussion at the meeting because they acted before the meeting. On the other hand they could wait for the Annual Meeting to break the quiet period, then it could be meaningful.
If we don't have the Journal by early July you may be correct that the meeting may not occur in July at all, or later in July if the Journal comes by mid month. I do not believe the company will ask investors to vote to authorize additional shares prior to the Journal being available.
If the Journal is not held up by anything due from Dr. Liau or the company, but rather were awaiting the official guidance change by the FDA, then no telling how long the Journal will be on hold. The Annuls of Oncology article by the FDA staff clearly specifies their intent to make the change, but if the Journal were insisting on the formal change being issued, no telling how long we may have to wait.